---
title: "Ionis Pharmaceuticals Drops 8% in Trading as Phase 3 Trial Misses Primary Endpoint"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292343951.md"
description: "Ionis shares fall 8% after Phase 3 CARDIO-TTRansform trial failure, extending losses from previous session."
datetime: "2026-07-10T16:50:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292343951.md)
  - [en](https://longbridge.com/en/news/292343951.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292343951.md)
generator: "portal-rs"
---

# Ionis Pharmaceuticals Drops 8% in Trading as Phase 3 Trial Misses Primary Endpoint

Ionis 制药 (IONS.US) 盘中跌**8.14%**，现报**59.04 美元**。

此次下跌延续了昨日跌势。7 月 10 日，该公司宣布与 AstraZeneca 合作的 Phase 3 CARDIO-TTRansform 试验未能达到主要疗效终点，研究显示在标准治疗基础上加用 eplontersen 未显示显著益处，导致股价当日下跌近 9%。多家律师事务所已就此启动证券调查。

分析师认为，此次试验失败对竞争对手如 Alnylam 的 Amvuttra 和 Pfizer 的 tafamidis 构成利好，进一步巩固了单一疗法的市场地位。该股当日成交量达**581.18 万股**，交投活跃。

### Related Stocks

- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)

## Related News & Research

- [Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/296455358.md)
- [This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday](https://longbridge.com/en/news/296352846.md)
- [Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $106.00 at Barclays](https://longbridge.com/en/news/280641184.md)
- [How TRYNGOLZA Approval and New Equity Shelf At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story](https://longbridge.com/en/news/295401431.md)
- [Ionis Q2 adjusted operating loss narrows](https://longbridge.com/en/news/294198021.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**